Medtech company Coloplast is taking a further important step in its quest to turn its US dreams into reality.
Coloplast has successfully won a large contract with the largest group purchasing organization (GPO) in the US, Vizient, which can be highly significant for the firm's long-term growth ambitions.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.